健康の
未来を実現しよう

First in the Rethinking Influence: Signals, Systems, and Strategy series, this piece reframes pharma’s influencer model as built on trust and continuity rather than speed.

Now that bispecifics have cleared the clinical bar, explore how reimbursement risk, care-setting economics, and payer confidence will determine which therapies scale.

Explore the macro trends reshaping oncology, from the pace of FDA approvals and liquid biopsy to AI, and what each means for pharma brand teams.

A companion to “Strategist’s Dilemma 2: Brand Building Begins from Within,” download this worksheet to start defining and developing your personal brand.

The biggest launch mistake is treating every brand like it needs the same playbook. Discover our five archetypes to learn which one is right for your brand launch.

Jasmine Singh, EVP, Medical Strategy – Growth and Innovation, Klick Health, sits down with Dr. Sanjay Juneja, practicing hematologist and oncologist, to talk about where AI is alre...

Women face diagnostic delays and worsened outcomes due to gender bias. Discover the key conditions driving this gap and how brands can help close it.

This article, part of the We’re Looking at Healthcare All Wrong series, explores how patients define value in healthcare and why financial structure so often stands between them an...

Why do some effective therapies struggle with adherence? Discover how closing the “felt benefit gap” can improve patient initiation, trust, and persistence.